Underestimation of Vertebral Fractures After Denosumab Discontinuation.
Details
![Ressource 1](https://serval.unil.ch/static/img/forbidden.png)
UNIL restricted access
State: Public
Version: author
License: Not specified
Serval ID
serval:BIB_4B76119EAB6D
Type
Article: article from journal or magazin.
Publication sub-type
Letter (letter): Communication to the publisher.
Collection
Publications
Institution
Title
Underestimation of Vertebral Fractures After Denosumab Discontinuation.
Journal
Journal of bone and mineral research
ISSN
1523-4681 (Electronic)
ISSN-L
0884-0431
Publication state
Published
Issued date
03/2018
Peer-reviewed
Oui
Volume
33
Number
3
Pages
547
Language
english
Notes
Publication types: Letter
Publication Status: ppublish
Publication Status: ppublish
Abstract
We have read with interest the article on vertebral fractures after stopping Denosumab by Cummings SR et al. (1). Denosumab discontinuation is followed by a rebound effect with an increase of CTX above baseline values for two years and a decrease of BMD to baseline value after one year (2). Spontaneous clinical vertebral fractures, most often multiple, occur in the 8 to 16 months (median 11.2 months) following the last Denosumab injection (3). The risk of clinical vertebral fractures in the 12 months following the last Denosumab injection was evaluated at 7.3% (4). This risk is certainly higher with a follow-up of 16 months and the inclusion of non clinical fractures. Cummings SR et al. calculate an exposure-adjusted participant incidence of vertebral fractures (radiological and clinical) of 7.1 per 100 participant-years, from which only 39.3% where clinical fractures. We think that the difference between the previously published data and the actual study is due to the fact that the duration of the follow-up was not sufficient to capture all the vertebral fractures. Moreover, we found that this study has methodological caveats.
Keywords
Antiresorptives, CLINICAL TRIALS, DISEASES AND DISORDERS OF/RELATED TO BONE, DXA ANALYSIS/QUANTITATION OF BONE, Fracture risk assessment, Osteoporosis, PRACTICE/POLICY-RELATED ISSUES, THERAPEUTICS
Pubmed
Web of science
Create date
08/02/2018 19:48
Last modification date
23/01/2020 7:19